Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados

Autores:: Mora Padilla, Edmundo
Ordoñez Vasquez, Mario Jesús
Luna Caffroni, Jackelineth
Casanova Libreros , Rosangela

Tipo de recurso:: Article of journal

Fecha de publicación:: 2020

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_620cb0134a4e6e71f188c05809e80015
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/3063
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
dc.title.translated.eng.fl_str_mv	Adjuvant chemotherapy in advanced stage epithelial ovarian cancer
title	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
spellingShingle	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados carcinoma epitelial de ovario quimioterapia adyuvante efectos adversos epithelial ovarian carcinoma adjuvant chemotherapy adverse effects
title_short	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
title_full	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
title_fullStr	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
title_full_unstemmed	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
title_sort	Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados
dc.creator.fl_str_mv	Mora Padilla, Edmundo Ordoñez Vasquez, Mario Jesús Luna Caffroni, Jackelineth Casanova Libreros , Rosangela
dc.contributor.author.spa.fl_str_mv	Mora Padilla, Edmundo Ordoñez Vasquez, Mario Jesús Luna Caffroni, Jackelineth Casanova Libreros , Rosangela
dc.subject.spa.fl_str_mv	carcinoma epitelial de ovario quimioterapia adyuvante efectos adversos
topic	carcinoma epitelial de ovario quimioterapia adyuvante efectos adversos epithelial ovarian carcinoma adjuvant chemotherapy adverse effects
dc.subject.eng.fl_str_mv	epithelial ovarian carcinoma adjuvant chemotherapy adverse effects
publishDate	2020
dc.date.accessioned.none.fl_str_mv	2020-04-06 16:33:03 2022-06-29T19:39:25Z
dc.date.issued.none.fl_str_mv	2020-04-06
dc.date.available.none.fl_str_mv	2020-04-06 16:33:03 2022-06-29T19:39:25Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/3063
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228
identifier_str_mv	0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/3063 https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	International Agency for Research on Cancer. Global Cancer Observatory [Internet]. World Health Organization; 2021 [Consultado 2021]. Available from: https://gco.iarc.fr/ 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254 3. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients. Biomark Cancer. 2019;11:1179299X1986081. doi: 10.1177/1179299X19860815 4. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. http://dx.doi.org/10.1016/j.bpobgyn.2016.08.006} 5. Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, et al. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. JAMA Netw open. 2020;3(8):e2013940. doi: 10.1001/jamanetworkopen.2020.13940 6. Monk BJ, Randall LM, Grisham RN. The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ B. 2019;39:e141–51. doi: 10.1200/EDBK_239007 7. Trimbos JB. Surgical treatment of early-stage ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41(2017):60–70. http://dx.doi.org/10.1016/j.bpobgyn.2016.10.001 8. Bois A Du, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44. doi: 10.1002/cncr.24149 9. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010 10. Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020;11: 577869. doi: 10.3389/fimmu.2020.577869 11. Broekman KE, van Kruchten M, van Tinteren H, Sessa C, Jalving M, Reyners AKL. Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores. ESMO Open. 2021;6(4):100229. https://doi.org/10.1016/j.esmoop.2021.100229 12. Isabelle RC, Isabelle TF, Eric PL, Liu JF, Selle F, Poveda AM, et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol. 2016;34(36):4345–53. doi: 10.1200/JCO.2016.67.1891 13. Murphy M, Martin G, Mahmoudjafari Z, Bivona C, Grauer D, Henry D. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. J Oncol Pharm Pract. 2020;26(7):1566–74. doi: 10.1177/1078155219899460 14. Du Bois A, Lück HJ, Meier W et al. No TitCarboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.le. Semin Onco. 1997;24(5):s15–52. 15. Coleman RL, Hennessy BT, Coleman RL, Markman M. Fallopian, Including Cancer, Tube Cancer, Primary Peritoneal. NCCN. 2021;1. 16. Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243:250–68. http://dx.doi.org/10.1016/j.jconrel.2016.10.014 17. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505. doi: 10.1056/NEJMoa1810858 18. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. doi: 10.1200/JCO.2003.02.153 19. Huang CY, Cheng M, Lee NR, Huang HY, Lee WL, Chang WH, et al. Comparing paclitaxel-"carboplatin with paclitaxel-"cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer. Int J Environ Res Public Health. 2020;17(7):2213. doi: 10.3390/ijerph17072213
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2088
dc.relation.citationedition.spa.fl_str_mv	: Pre-Print
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía - 2020
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Revista Repertorio de Medicina y Cirugía - 2020 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/0089b1ce-d2ee-443e-a06e-62dcf79f66c8/download
bitstream.checksum.fl_str_mv	a501a85badafd9c54f6b926623664962
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1814355555290972160
spelling	Mora Padilla, Edmundo7d8893a2c8f1f299ecc527351c9d9af3Ordoñez Vasquez, Mario Jesús8feed70ae6847f206ad90d2b31758adf300Luna Caffroni, Jackelineth0aa9f869798fe0937d0c8f7a86fb8f10300Casanova Libreros , Rosangelacbfeb8e25b1c960133b3f107819fc40d3002020-04-06 16:33:032022-06-29T19:39:25Z2020-04-062020-04-06 16:33:032022-06-29T19:39:25ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la SaludRevista Repertorio de Medicina y Cirugía - 2020info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228carcinoma epitelial de ovarioquimioterapia adyuvanteefectos adversosepithelial ovarian carcinomaadjuvant chemotherapyadverse effectsQuimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzadosAdjuvant chemotherapy in advanced stage epithelial ovarian cancerapplication/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/coar/version/c_970fb48d4fbd8a850121-7372https://repositorio.fucsalud.edu.co/handle/001/30632462-991Xhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1228spaInternational Agency for Research on Cancer. Global Cancer Observatory [Internet]. World Health Organization; 2021 [Consultado 2021]. Available from: https://gco.iarc.fr/ 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254 3. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients. Biomark Cancer. 2019;11:1179299X1986081. doi: 10.1177/1179299X19860815 4. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. http://dx.doi.org/10.1016/j.bpobgyn.2016.08.006} 5. Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, et al. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. JAMA Netw open. 2020;3(8):e2013940. doi: 10.1001/jamanetworkopen.2020.13940 6. Monk BJ, Randall LM, Grisham RN. The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ B. 2019;39:e141–51. doi: 10.1200/EDBK_239007 7. Trimbos JB. Surgical treatment of early-stage ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41(2017):60–70. http://dx.doi.org/10.1016/j.bpobgyn.2016.10.001 8. Bois A Du, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44. doi: 10.1002/cncr.24149 9. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010 10. Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020;11: 577869. doi: 10.3389/fimmu.2020.577869 11. Broekman KE, van Kruchten M, van Tinteren H, Sessa C, Jalving M, Reyners AKL. Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores. ESMO Open. 2021;6(4):100229. https://doi.org/10.1016/j.esmoop.2021.100229 12. Isabelle RC, Isabelle TF, Eric PL, Liu JF, Selle F, Poveda AM, et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patientswith advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol. 2016;34(36):4345–53. doi: 10.1200/JCO.2016.67.1891 13. Murphy M, Martin G, Mahmoudjafari Z, Bivona C, Grauer D, Henry D. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. J Oncol Pharm Pract. 2020;26(7):1566–74. doi: 10.1177/1078155219899460 14. Du Bois A, Lück HJ, Meier W et al. No TitCarboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.le. Semin Onco. 1997;24(5):s15–52. 15. Coleman RL, Hennessy BT, Coleman RL, Markman M. Fallopian, Including Cancer, Tube Cancer, Primary Peritoneal. NCCN. 2021;1. 16. Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release. 2016;243:250–68. http://dx.doi.org/10.1016/j.jconrel.2016.10.014 17. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505. doi: 10.1056/NEJMoa1810858 18. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. doi: 10.1200/JCO.2003.02.153 19. Huang CY, Cheng M, Lee NR, Huang HY, Lee WL, Chang WH, et al. Comparing paclitaxel-"carboplatin with paclitaxel-"cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer. Int J Environ Res Public Health. 2020;17(7):2213. doi: 10.3390/ijerph17072213https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/1228/2088: Pre-PrintRevista Repertorio de Medicina y CirugíaPublicationOREORE.xmltext/xml2822https://repositorio.fucsalud.edu.co/bitstreams/0089b1ce-d2ee-443e-a06e-62dcf79f66c8/downloada501a85badafd9c54f6b926623664962MD51001/3063oai:repositorio.fucsalud.edu.co:001/30632024-02-02 13:09:17.085https://creativecommons.org/licenses/by-nc-sa/4.0/Revista Repertorio de Medicina y Cirugía - 2020metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados

Publicaciones similares